Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Drug Development Questions Dominate Hahn's Confirmation, Despite Talk About E-Cigs

Nov 20 2019

• By Michael Cipriano

Stephen Hahn, President Trump’s nominee for commissioner of the FDA, at his Senate confirmation hearing today — Stephen Hahn received a series of questions on drug development at his Senate confirmation hearing. • Source: Derrick Gingery

Related Content

Hahn Confirmation Hearing: Pharma May Be Left Parsing Non-Rx Questions For Policy Clues

Nov 18 2019

Stephen Hahn For US FDA Commissioner: Will Academic Experience Suffice For Confirmation?

Nov 01 2019

US FDA's New Drug Assessors More Experienced With Rare Disease Issues

Sep 11 2019

Senate Drug Pricing Legislation Clears Committee With Generic Exclusivity “Parking” Provision Unchanged

Jun 26 2019

Drug Development, Not Conflicts, Dominates Gottlieb's Confirmation Hearing

Apr 10 2017

Opioid Policy At US FDA: Gottlieb Seeks More Activist Role To Combat Abuse

Apr 07 2017

Complex Generics: Gottlieb Eyes FDA Policy Changes To Speed Approvals

Apr 06 2017

Additional Topics

United States FDA Leadership Regulation BioPharmaceutical

More from US FDA

More from Agency Leadership

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.